Bio-Techne Corp (TECH) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Bio-Techne Corp $33.66, price $72.52, upside -53.6%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Bio-Techne Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $43.22 – $131.32 · fair‑value band $31.97 – $43.70 · the $72.52 price screens above the $33.66 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Bio-Techne in your weekly email
Every Wednesday you see whether Bio-Techne is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Show more
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Stock analysis
Bio-Techne Corp (TECH) currently trades at $72.52, while our model-based Fair Value estimate is $33.66, implying the stock looks roughly 115.5% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $20.40 per share, and 0 of the 24 models we run sit above the $72.52 price.
Bear case: the Economic Profit group reads lowest at $4.32, and 24 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: $31.97 (bear) to $43.70 (bull), the price of $72.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Bio-Techne Corp reported revenue of $1.2B in FY2025 versus $931M in FY2021, a compound +7.0%/yr. Reported net income was $73.4M in FY2025, compounding −15.0%/yr from FY2021.
Key figures
Market cap $11.6B · P/E ratio 103.6 · P/S ratio 6.23 · EPS (TTM) $0.7000 · Dividend yield 0.4% · Net margin 6.0% · Return on equity 5.3% · Return on assets (EBIT) 9.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 68% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −54%, TECH screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($4.32 to $36.88). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $31.97Fair Value $33.66Bull $43.70
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($0.3800 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+5.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
Start year 2020 (pandemic). Over 10 years: +10.4% a year
Revenue growth 36 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−2.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.8%
Dividend (yield on the price)0.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12% vs −4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 8%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+27.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +24.9% a year for the price and −0.5% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (94 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 6/15 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−54% · Below median
Profitability
Return on equity (TTM)5% · Above median
Return on assets7% · Top 25%
Net margin (TTM)9% · Above median
Operating margin (TTM)25% · Top 25%
Growth and dividend
Revenue growth−2% · Below median
Dividend yield (TTM)0.4% · Bottom 25%
Balance sheet
Debt / equity0.18× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)103.6× · Priciest 25%
P/B6.04× · Priciest 25%
P/S (TTM)9.57× · Pricier than median
P/FCF45.2× · Priciest 25%
EV/EBITDA32.2× · Pricier than median
PEG0.96× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)21· sector 0
HEALTH (low debt)91· sector 97
DIVIDEND (yield)9· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Bio-Techne Corp Fair Value". https://www.fairvalue-calculator.com/stock/TECH
Frequently asked questions
Is Bio-Techne Corp (TECH) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $33.66 versus a price of $72.52, about −54% upside (overvalued).
What is the fair value of TECH?
Our model-based fair value for Bio-Techne Corp is $33.66 (as of Sep 24, 2026), built from audited fundamentals. The current price: $72.52.
What is the quality score of TECH?
Bio-Techne Corp has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bio-Techne Corp (TECH)?
Our model-based price target is the fair value of $33.66 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $31.97, optimistic scenario $43.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Bio-Techne Corp stock forecast for 2026?
Our models put fair value at $33.66, about −54% upside versus a price of $72.52 (overvalued). Cautious scenario $31.97, optimistic scenario $43.70. The calculation is refreshed regularly with new filings.
What is the revenue of Bio-Techne Corp (TECH)?
Bio-Techne Corp reported trailing-twelve-month revenue of about $1.2B (latest available figure, as of Sep 24, 2026).
Does Bio-Techne Corp pay a dividend?
Bio-Techne Corp currently shows a dividend yield of about 0.44% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Bio-Techne Corp (TECH)?
For today's price to be fair in a discounted-cash-flow model, Bio-Techne Corp would have to grow free cash flow by +27.9 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of TECH use?
Our models discount Bio-Techne Corp at 10.6 %: a base by market capitalisation (mid), damped by beta 1.36, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bio-Techne Corp that is +27.9 % per year a year over ten years, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Bio-Techne Corp (TECH) delivered so far?
Over the past 5 years revenue at Bio-Techne Corp grew +10.6 % a year. The price currently implies +27.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bio-Techne Corp (TECH) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Bio-Techne Corp (+27.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bio-Techne Corp (TECH)?
The free-cash-flow yield on the price is 2.21 %: that much free cash flow Bio-Techne Corp produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bio-Techne Corp (TECH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bio-Techne Corp it is $33.66 per share (as of Sep 24, 2026), against a price of $72.52. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Bio-Techne Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, TECH trades above its calculated fair value: price $72.52, fair value $33.66, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TECH?
No. The price is what the market pays today ($72.52); the fair value is what the company's own numbers justify ($33.66). For Bio-Techne Corp the two are $38.86 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bio-Techne Corp worth?
The market values Bio-Techne Corp at about $11.6B (market capitalisation, as of Sep 24, 2026). Per share that is $72.52; our models calculate a fair value of $33.66 per share.
What do the bullish and bearish scenarios say about TECH?
Our models span a range for Bio-Techne Corp: cautious scenario $31.97, base $33.66, optimistic $43.70 per share (as of Sep 24, 2026, price $72.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TECH?
Bio-Techne Corp trades at a price-to-earnings ratio of 103.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $33.66 is built from several models across several years. Other multiples: PEG 1.0, P/B 6.0, P/S 9.6, EV/EBITDA 32.2.
What is the PEG ratio of TECH?
The PEG ratio of Bio-Techne Corp is 0.96 (P/E divided by earnings growth, as of Sep 24, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Bio-Techne Corp (TECH)?
Balance-sheet figures for Bio-Techne Corp (as of Sep 24, 2026): return on equity 5.3%, debt of 0.18 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is TECH from its 52-week high?
Bio-Techne Corp trades at $72.52, at its 52-week high of $72.55 and 68% above the low of $43.22 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $33.66 is for.
Which stocks are comparable to Bio-Techne Corp?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bio-Techne Corp stock attractive at the current price?
The data as of Sep 24, 2026: price $72.52, calculated fair value $33.66 (−54%), Quality Score 67/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TECH calculated?
We run Bio-Techne Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $33.66, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Bio-Techne Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bio-Techne Corp (TECH)?
The closing price on Sep 23, 2026 was $72.52. Our model-based fair value is $33.66, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bio-Techne Corp right now?
The price sits above even our optimistic bull case ($43.70). The favourable scenario is already priced in. Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Bio-Techne Corp (TECH) come from?
Earnings per share at Bio-Techne Corp grew +4.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +10.6 %, EBIT margin −7.5 %, tax rate +2.2 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bio-Techne Corp
How large is the market capitalisation of Bio-Techne Corp (TECH)?
The market capitalisation of Bio-Techne Corp is $11.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bio-Techne Corp (TECH)?
The price-to-sales ratio of Bio-Techne Corp is 6.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bio-Techne Corp (TECH)?
Earnings per share at Bio-Techne Corp are $0.7000 (price ÷ EPS = P/E 103.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bio-Techne Corp (TECH)?
The dividend yield of Bio-Techne Corp is 0.4% (payout 45.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bio-Techne Corp (TECH)?
The net margin of Bio-Techne Corp is 6.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bio-Techne Corp (TECH)?
The return on equity (ROE) of Bio-Techne Corp is 5.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bio-Techne Corp (TECH)?
On an EBIT basis the return on assets of Bio-Techne Corp is 9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bio-Techne Corp (TECH)?
The operating margin of Bio-Techne Corp is 25.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bio-Techne Corp (TECH)?
Revenue at Bio-Techne Corp is growing −1.5% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bio-Techne Corp (TECH)?
Earnings per share at Bio-Techne Corp are growing +129% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bio-Techne Corp (TECH) carry?
The net debt of Bio-Techne Corp is $282M (fiscal year 2025, ≈ 1.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bio-Techne Corp in the live analysis
One click puts Bio-Techne Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Sep 24, 2026